The acquisition of Dynamic Biosensors GmbH by Bruker is strategically significant as it enhances Bruker's capabilities in molecular interaction analysis, a key area in drug discovery and research. The expected revenue increase of over $5 million by FY2025 indicates a positive financial impact, although it is not expected to significantly affect EPS. This suggests a moderate positive impact on Bruker's stock price in the short term.